A tumor-specific neoepitope expressed in homologous/self or heterologous/viral antigens induced comparable effector CD8+ T-cell responses by DNA vaccination

Stifter, Katja; Dekhtiarenko, Iryna; Krieger, Jana; Tissot, Alain C.; Seufferlein, Thomas; Wagner, Martin; Schirmbeck, Reinhold

doi:10.1016/j.vaccine.2020.04.003

Cited by 11 publications

(6 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in a recent study, researchers constructed a Db/Sp244-252/R251H neoantigen epitope (changing an amino acid site) in the EndoB2-Sp protein and found that a single injection of the EndoB2-Sp expression vector into C57Bl/6j mice could effectively induce activation of IFN-γ + CD8+ T cells specifically targeting the neoantigen epitope (Db/Sp244-252/R251H). The expression of Db/Sp244-252/R251H within the core antigen of assembly-deficient HBV induced a considerable number of CD8+ T cells specifically targeting Db/Sp244-252/R251H compared with the EndoB2-Sp vaccine [ 26 ].…”

Section: Conception Of Combing Neoantigen Mrna Vaccine and Icis For T...mentioning

confidence: 99%

Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment

Han,

Wang,

2023

Pharmaceutics

View full text Add to dashboard Cite

This study builds upon the groundbreaking mRNA vaccine Nobel Prize win in 2023 for COVID-19 prevention, paving the way for next-generation mRNA cancer vaccines to revolutionize immunotherapy. Despite the existing challenges, such as the presence of a suppressive tumor microenvironment and the identification of cancer-associated antigens, recent results from the KEYNOTE-942 trial have successfully demonstrated the effectiveness of mRNA-based cancer treatments, providing clinical evidence for the first time. This trial aimed to evaluate the efficacy and safety of combining immune checkpoint inhibitors with mRNA-based therapies in treating cancer. This advancement undeniably represents new hope for hepatocellular carcinoma (HCC) patients. However, progress in this field remains limited. In this article, we summarized the current state of applying immune checkpoint inhibitors (ICIs) combined with neoantigen mRNA vaccines. Additionally, we discussed potential targets for designing novel mRNA vaccines and potential mRNA vaccine delivery vehicles. The objective of this article is to inspire enthusiasm for the exploration of innovative therapeutic strategies that combine ICIs with neoantigen mRNA vaccines for HCC treatment and HCC prevention.

show abstract

Section: Conception Of Combing Neoantigen Mrna Vaccine and Icis For T...mentioning

confidence: 99%

Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment

Han,

Wang,

2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Endophilin B1 is mainly localized in intracellular membrane, and Endophilin B1 is also localized at mitochondrial membranes, golgi membranes and autophagosomal membranes ( 16 ). Endophilin B2 is expressed in skeletal muscle, adipose tissue, lung, brain and mammary gland ( 17 ).…”

Section: Subtypes and Structurementioning

confidence: 99%

Biology of endophilin and it’s role in disease

Yang,

Huang,

2023

Front. Immunol.

View full text Add to dashboard Cite

Endophilin is an evolutionarily conserved family of protein that involves in a range of intracellular membrane dynamics. This family consists of five isoforms, which are distributed in various tissues. Recent studies have shown that Endophilin regulates diseases pathogenesis, including neurodegenerative diseases, tumors, cardiovascular diseases, and autoimmune diseases. In vivo, it regulates different biological functions such as vesicle endocytosis, mitochondrial morphological changes, apoptosis and autophagosome formation. Functional studies confirmed the role of Endophilin in development and progression of these diseases. In this study, we have comprehensively discussed the complex function of Endophilin and how the family contributes to diseases development. It is hoped that this study will provide new ideas for targeting Endophilin in diseases.

show abstract

“…It has also been shown that oncolytic virus plasmids have the capability of coding for PD-L1 inhibitors themselves, allowing for neoantigen recognition by T cells [80]. Additional experiments have tested the efficacy of linking neoantigen peptides to diphtheria toxin and HBV platforms with varying results [81,82].…”

Section: Immune Primingmentioning

confidence: 99%

Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies

et al. 2022

View full text Add to dashboard Cite

Alternatives to conventional cancer treatments are highly sought after for high-risk malignancies that have a poor response to established treatment modalities. With research advancing rapidly in the past decade, neoantigen-based immunotherapeutic approaches represent an effective and highly tolerable therapeutic option. Neoantigens are tumor-specific antigens that are not expressed in normal cells and possess significant immunogenic potential. Several recent studies have described the conceptual framework and methodologies to generate neoantigen-based vaccines as well as the formulation of appropriate clinical trials to advance this approach for patient care. This review aims to describe some of the key studies in the recent literature in this rapidly evolving field and summarize the current advances in neoantigen identification and selection, vaccine generation and delivery, and the optimization of neoantigen-based therapeutic strategies, including the early data from pivotal clinical studies.

show abstract

A tumor-specific neoepitope expressed in homologous/self or heterologous/viral antigens induced comparable effector CD8+ T-cell responses by DNA vaccination

Cited by 11 publications

References 67 publications

Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment

Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment

Biology of endophilin and it’s role in disease

Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies

Contact Info

Product

Resources

About